Development of technologies for evaluation of antibody response following Coronavirus Infection vs Vaccination to identify immune correlates of protection

武汉新型冠状病毒（nCoV）的出现促使人们努力迅速开发有效的医疗对策，包括针对这一严重疾病的疫苗和治疗方法。然而，关于动物或人接种疫苗或感染新型冠状病毒后产生的多克隆抗体反应的知识有限。重要的是要识别和了解合理可能预测临床获益的免疫标记，并有助于评估疫苗和候选治疗方法，包括：1 .不同的疫苗平台在人类和动物中是否会引发相似或不同的抗体表位库、抗体同型、抗体亲和力和持久性？2。预防SARS-CoV-2的相关因素是什么：刺突蛋白内特定抗原区域的总抗体结合？抗体亲和力?抗体同形像?抗体表位多样性？3。新型冠状病毒疫苗产生的抗体的数量、质量（表位和亲和力）和持久性与感染后（急性期和恢复期）血清中发现的抗体相似还是不同？为了弥补这些空白，我们将开发先进技术，包括针对新型冠状病毒的全基因组噬菌体展示文库（GFPDL）和SPR，以深入分析动物模型或人类接种疫苗和感染新型冠状病毒后的免疫反应。

The emergence of the Wuhan new coronavirus (nCoV) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or nCoV infection in animals or humans. It is important to identify and understand immune markers that are reasonably likely to predict clinical benefit and that can facilitate evaluation of vaccine and therapeutic candidates, including: I. Do different vaccine platforms elicit similar or different antibody epitope repertoires, antibody isotypes, antibody affinity and durability in human’s vs animals? II. What are the correlates of protection against SARS-CoV-2: Total antibody binding to specific antigenic regions within spike protein? antibody affinity? antibody isotype? antibody epitope diversity? III. Is the quantity, quality (epitopes and affinity) and durability of antibodies generated by nCoV- vaccination is similar or different than those of antibodies found in post-infection (in acute and convalescent) sera? To address these gaps, we will develop advanced technologies, including whole genome phage display library (GFPDL) and SPR for the new Coronavirus (nCoV) for in-depth analysis of immune responses following vaccination and nCoV infection in animal models or humans.